PATENT CLAIM ANALYSIS

Application Number: 15948406
Application Type: Utility
Filing Date: 2018-04
Publication Date: 2018-10
Patent Classification: ["514", "256000"]

Abstract:
The present disclosure provides compositions comprising a lyn kinase activator and TRPM8 agonist, and to methods of: reducing blood glucose levels, weight gain, or fat depot levels; treating metabolic syndrome, Syndrome X, obesity, prediabetes, type II diabetes, type I diabetes; treating hypercholesterolemia, hypertension, coronary heart disease, diabetic neuropathy, lipodystrophy, diabetic retinopathy, erectile dysfunction, kidney disease, dyslipidemia, dyslipoproteinemia, a peroxisome proliferator activated receptor-associated disorder, septicemia, a thrombotic disorder, or pancreatitis; inducing the beiging of adipocytes; and preventing pancreatic beta cell degeneration.

Claim (Index 8):
The composition of  claim 1 , wherein the lyn kinase activator is of the formula: or a pharmaceutically acceptable salt thereof.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 91.0
- Lexical Diversity: 1.50704
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['12495857', '15543826', '15326890', '14033176', '15807301']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.788677638650554
- 35 USC 102 Novelty (BERT): 0.5361485535559879
- Combined Prediction Score: 0.7634247301410975
- Mean Citation Score: 296.775864
- Max Citation Score: 370.219
- Similarity Product: 264.7647212347984

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test